CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Dr. Bo Liang
Advertisement
Dr. Bo Liang is chief medical officer at CORXEL.
Articles by Dr. Bo Liang
CORXEL’s Dr. Bo Liang on why GLP-1 therapies are a broader chronic disease platform — not just obesity drugs — with benefits across cardiovascular, renal, and metabolic disease.
Why GLP-1s achieving bariatric surgery-level efficacy is the field's most surprising advancement of the past decade.
CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
2
Pharmaceutical Executive Daily: FDA Grants Accelerated Approval to Jemperli
3
CSL Names Deborah Waterhouse as CEO and Manager Director
4
How MFN Deals May Impact Future Decisions
5